{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.6","value":"22.8"},{"groupId":"OG001","spread":"22.5","value":"25.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"220"},{"groupId":"OG001","value":"111"}],"units":"Participants"}],"title":"Abdominal/GI Score at Screening"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.1","value":"29.3"},{"groupId":"OG001","spread":"17.7","value":"22.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"81"}],"units":"Participants"}],"title":"Abdominal/GI Score at Week 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.6","value":"26.7"},{"groupId":"OG001","spread":"15.9","value":"20.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"67"}],"units":"Participants"}],"title":"Abdominal/GI Score at Week 17"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.6","value":"22.1"},{"groupId":"OG001","spread":"17.2","value":"20.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"title":"Abdominal/GI Score at Week 25"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.3","value":"27.2"},{"groupId":"OG001","spread":"18.3","value":"15.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"title":"Abdominal/GI Score at Week 33"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.3","value":"26.9"},{"groupId":"OG001","spread":"23.0","value":"18.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"title":"Abdominal/GI Score at Week 41"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.5","value":"23.5"},{"groupId":"OG001","spread":"20.7","value":"17.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Abdominal/GI Score at Week 49"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.4","value":"26.1"},{"groupId":"OG001","spread":"19.3","value":"18.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Abdominal/GI Score at Week 57"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.4","value":"26.0"},{"groupId":"OG001","spread":"23.1","value":"23.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Abdominal/GI Score at Week 65"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.3","value":"23.0"},{"groupId":"OG001","spread":"29.1","value":"31.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Abdominal/GI Score at Week 73"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.0","value":"31.6"},{"groupId":"OG001","spread":"20.4","value":"24.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"title":"Abdominal/GI Score at Treatment Discontinuation Visit"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.6","value":"31.8"},{"groupId":"OG001","spread":"22.1","value":"17.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"Abdominal/GI Score at 30-Day Safety Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.1","value":"16.6"},{"groupId":"OG001","spread":"22.4","value":"14.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"220"},{"groupId":"OG001","value":"110"}],"units":"Participants"}],"title":"Peripheral neuropathy Score at Screening"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.9","value":"26.7"},{"groupId":"OG001","spread":"23.5","value":"19.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"81"}],"units":"Participants"}],"title":"Peripheral neuropathy Score at Week 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.8","value":"27.1"},{"groupId":"OG001","spread":"21.6","value":"20.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"67"}],"units":"Participants"}],"title":"Peripheral neuropathy Score at Week 17"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"31.0","value":"30.2"},{"groupId":"OG001","spread":"24.2","value":"21.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"title":"Peripheral neuropathy Score at Week 25"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.7","value":"30.4"},{"groupId":"OG001","spread":"24.4","value":"21.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"title":"Peripheral neuropathy Score at Week 33"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.1","value":"25.2"},{"groupId":"OG001","spread":"16.4","value":"14.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"title":"Peripheral neuropathy Score at Week 41"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.1","value":"25.0"},{"groupId":"OG001","spread":"18.1","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Peripheral neuropathy Score at Week 49"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.9","value":"22.5"},{"groupId":"OG001","spread":"23.9","value":"15.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Peripheral neuropathy Score at Week 57"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.8","value":"18.7"},{"groupId":"OG001","spread":"26.1","value":"22.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Peripheral neuropathy Score at Week 65"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.2","value":"17.2"},{"groupId":"OG001","spread":"30.9","value":"25.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Peripheral neuropathy Score at Week 73"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.4","value":"28.5"},{"groupId":"OG001","spread":"24.4","value":"22.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"title":"Peripheral neuropathy Score at Treatment Discontinuation Visit"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.8","value":"28.9"},{"groupId":"OG001","spread":"32.5","value":"23.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"Peripheral neuropathy Score at 30-Day Safety Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.5","value":"22.0"},{"groupId":"OG001","spread":"28.4","value":"23.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"220"},{"groupId":"OG001","value":"110"}],"units":"Participants"}],"title":"Hormonal Score at Screening"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.5","value":"10.2"},{"groupId":"OG001","spread":"28.9","value":"23.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"81"}],"units":"Participants"}],"title":"Hormonal Score at Week 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.8","value":"9.3"},{"groupId":"OG001","spread":"28.1","value":"23.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"67"}],"units":"Participants"}],"title":"Hormonal Score at Week 17"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"11.5","value":"6.2"},{"groupId":"OG001","spread":"26.2","value":"23.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"title":"Hormonal Score at Week 25"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.0","value":"11.6"},{"groupId":"OG001","spread":"29.0","value":"23.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"title":"Hormonal Score at Week 33"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.9","value":"13.4"},{"groupId":"OG001","spread":"29.9","value":"21.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"title":"Hormonal Score at Week 41"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.3","value":"13.8"},{"groupId":"OG001","spread":"34.4","value":"25.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Hormonal Score at Week 49"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.6","value":"11.2"},{"groupId":"OG001","spread":"38.0","value":"33.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Hormonal Score at Week 57"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.8","value":"9.8"},{"groupId":"OG001","spread":"38.3","value":"25.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Hormonal Score at Week 65"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"13.3","value":"8.1"},{"groupId":"OG001","spread":"28.8","value":"14.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Hormonal Score at Week 73"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.7","value":"14.8"},{"groupId":"OG001","spread":"34.0","value":"26.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"title":"Hormonal Score at Treatment Discontinuation Visit"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.8","value":"22.4"},{"groupId":"OG001","spread":"21.4","value":"14.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"Hormonal Score at 30-Day Safety Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.3","value":"28.9"},{"groupId":"OG001","spread":"31.9","value":"31.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"217"},{"groupId":"OG001","value":"111"}],"units":"Participants"}],"title":"Body image Score at Screening"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.1","value":"42.1"},{"groupId":"OG001","spread":"30.1","value":"36.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"80"}],"units":"Participants"}],"title":"Body image Score at Week 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.6","value":"40.1"},{"groupId":"OG001","spread":"29.9","value":"32.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"67"}],"units":"Participants"}],"title":"Body image Score at Week 17"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.1","value":"37.4"},{"groupId":"OG001","spread":"25.4","value":"27.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"47"}],"units":"Participants"}],"title":"Body image Score at Week 25"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.7","value":"36.2"},{"groupId":"OG001","spread":"29.1","value":"28.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"title":"Body image Score at Week 33"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.8","value":"40.4"},{"groupId":"OG001","spread":"31.2","value":"30.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"title":"Body image Score at Week 41"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.8","value":"36.2"},{"groupId":"OG001","spread":"32.5","value":"25.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Body image Score at Week 49"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.0","value":"36.1"},{"groupId":"OG001","spread":"26.5","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Body image Score at Week 57"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.0","value":"33.7"},{"groupId":"OG001","spread":"30.2","value":"25.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Body image Score at Week 65"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.4","value":"27.8"},{"groupId":"OG001","spread":"34.5","value":"33.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Body image Score at Week 73"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.9","value":"46.9"},{"groupId":"OG001","spread":"32.0","value":"37.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"title":"Body image Score at Treatment Discontinuation Visit"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"30.5","value":"35.0"},{"groupId":"OG001","spread":"26.8","value":"23.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"Body image Score at 30-Day Safety Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.6","value":"48.0"},{"groupId":"OG001","spread":"29.1","value":"51.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"216"},{"groupId":"OG001","value":"110"}],"units":"Participants"}],"title":"Attitude to disease/treatment Score at Screening"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.5","value":"49.5"},{"groupId":"OG001","spread":"26.5","value":"47.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"169"},{"groupId":"OG001","value":"80"}],"units":"Participants"}],"title":"Attitude to disease/treatment Score at Week 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.2","value":"46.1"},{"groupId":"OG001","spread":"26.1","value":"51.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"67"}],"units":"Participants"}],"title":"Attitude to disease/treatment Score at Week 17"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.2","value":"39.0"},{"groupId":"OG001","spread":"26.5","value":"44.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"47"}],"units":"Participants"}],"title":"Attitude to disease/treatment Score at Week 25"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.9","value":"41.8"},{"groupId":"OG001","spread":"24.8","value":"44.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"title":"Attitude to disease/treatment Score at Week 33"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.1","value":"44.3"},{"groupId":"OG001","spread":"23.1","value":"40.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"title":"Attitude to disease/treatment Score at Week 41"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.7","value":"37.2"},{"groupId":"OG001","spread":"23.6","value":"38.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Attitude to disease/treatment Score at Week 49"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.0","value":"38.8"},{"groupId":"OG001","spread":"27.1","value":"32.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Attitude to disease/treatment Score at Week 57"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.6","value":"37.4"},{"groupId":"OG001","spread":"28.7","value":"45.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Attitude to disease/treatment Score at Week 65"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.3","value":"37.7"},{"groupId":"OG001","spread":"43.6","value":"51.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Attitude to disease/treatment Score at Week 73"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.5","value":"55.8"},{"groupId":"OG001","spread":"29.3","value":"53.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"title":"Attitude to disease/treatment Score at Treatment Discontinuation Visit"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"27.0","value":"49.3"},{"groupId":"OG001","spread":"24.9","value":"50.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"Attitude to disease/treatment Score at 30-Day Safety Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.0","value":"17.7"},{"groupId":"OG001","spread":"14.7","value":"17.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"220"},{"groupId":"OG001","value":"110"}],"units":"Participants"}],"title":"Chemotherapy Side Effects Score at Screening"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.4","value":"28.6"},{"groupId":"OG001","spread":"16.2","value":"22.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"81"}],"units":"Participants"}],"title":"Chemotherapy Side Effects Score at Week 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.3","value":"27.1"},{"groupId":"OG001","spread":"15.2","value":"24.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"67"}],"units":"Participants"}],"title":"Chemotherapy Side Effects Score at Week 17"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.5","value":"27.7"},{"groupId":"OG001","spread":"18.1","value":"25.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"title":"Chemotherapy Side Effects Score at Week 25"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.4","value":"28.8"},{"groupId":"OG001","spread":"17.1","value":"24.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"title":"Chemotherapy Side Effects Score at Week 33"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.2","value":"30.1"},{"groupId":"OG001","spread":"20.8","value":"23.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"title":"Chemotherapy Side Effects Score at Week 41"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.5","value":"29.5"},{"groupId":"OG001","spread":"18.6","value":"23.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Chemotherapy Side Effects Score at Week 49"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.5","value":"27.9"},{"groupId":"OG001","spread":"18.3","value":"23.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Chemotherapy Side Effects Score at Week 57"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.1","value":"25.5"},{"groupId":"OG001","spread":"15.4","value":"25.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Chemotherapy Side Effects Score at Week 65"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.4","value":"27.7"},{"groupId":"OG001","spread":"20.5","value":"29.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Chemotherapy Side Effects Score at Week 73"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.6","value":"30.4"},{"groupId":"OG001","spread":"19.4","value":"28.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"title":"Chemotherapy Side Effects Score at Treatment Discontinuation Visit"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.5","value":"27.5"},{"groupId":"OG001","spread":"14.7","value":"17.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"Chemotherapy Side Effects Score at 30-Day Safety Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.5","value":"11.8"},{"groupId":"OG001","spread":"19.6","value":"14.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"220"},{"groupId":"OG001","value":"111"}],"units":"Participants"}],"title":"Other Score at Screening"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.4","value":"22.0"},{"groupId":"OG001","spread":"20.6","value":"23.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"171"},{"groupId":"OG001","value":"81"}],"units":"Participants"}],"title":"Other Score at Week 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"22.2","value":"26.1"},{"groupId":"OG001","spread":"19.1","value":"20.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"134"},{"groupId":"OG001","value":"67"}],"units":"Participants"}],"title":"Other Score at Week 17"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.1","value":"22.9"},{"groupId":"OG001","spread":"17.5","value":"18.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"},{"groupId":"OG001","value":"46"}],"units":"Participants"}],"title":"Other Score at Week 25"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.3","value":"22.3"},{"groupId":"OG001","spread":"19.4","value":"16.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"32"}],"units":"Participants"}],"title":"Other Score at Week 33"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.2","value":"19.1"},{"groupId":"OG001","spread":"15.1","value":"14.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"25"}],"units":"Participants"}],"title":"Other Score at Week 41"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.6","value":"19.0"},{"groupId":"OG001","spread":"13.6","value":"12.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Other Score at Week 49"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.5","value":"16.3"},{"groupId":"OG001","spread":"17.0","value":"16.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Other Score at Week 57"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.9","value":"15.4"},{"groupId":"OG001","spread":"24.5","value":"22.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Other Score at Week 65"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.0","value":"15.7"},{"groupId":"OG001","spread":"22.0","value":"22.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Other Score at Week 73"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.9","value":"22.1"},{"groupId":"OG001","spread":"20.1","value":"22.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"109"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"title":"Other Score at Treatment Discontinuation Visit"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.0","value":"17.2"},{"groupId":"OG001","spread":"20.4","value":"14.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"title":"Other Score at 30-Day Safety Follow-up"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.3","value":"20.2"},{"groupId":"OG001","spread":"21.9","value":"19.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"200"},{"groupId":"OG001","value":"106"}],"units":"Participants"}],"title":"Sexuality Score at Screening"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.4","value":"18.7"},{"groupId":"OG001","spread":"21.9","value":"18.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"78"}],"units":"Participants"}],"title":"Sexuality Score at Week 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.3","value":"19.6"},{"groupId":"OG001","spread":"21.6","value":"18.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"65"}],"units":"Participants"}],"title":"Sexuality Score at Week 17"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.5","value":"21.8"},{"groupId":"OG001","spread":"23.8","value":"22.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"44"}],"units":"Participants"}],"title":"Sexuality Score at Week 25"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"23.0","value":"25.8"},{"groupId":"OG001","spread":"21.7","value":"21.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"29"}],"units":"Participants"}],"title":"Sexuality Score at Week 33"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.0","value":"21.3"},{"groupId":"OG001","spread":"23.1","value":"19.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"title":"Sexuality Score at Week 41"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.9","value":"23.0"},{"groupId":"OG001","spread":"23.0","value":"20.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"Sexuality Score at Week 49"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.8","value":"21.8"},{"groupId":"OG001","spread":"24.7","value":"18.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"37"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"title":"Sexuality Score at Week 57"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.7","value":"21.3"},{"groupId":"OG001","spread":"15.8","value":"12.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"Sexuality Score at Week 65"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.6","value":"20.8"},{"groupId":"OG001","spread":"16.6","value":"11.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"title":"Sexuality Score at Week 73"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.4","value":"14.2"},{"groupId":"OG001","spread":"23.0","value":"23.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"95"},{"groupId":"OG001","value":"42"}],"units":"Participants"}],"title":"Sexuality Score at Treatment Discontinuation Visit"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.8","value":"15.6"},{"groupId":"OG001","spread":"25.8","value":"26.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Sexuality Score at 30-Day Safety Follow-up"}],"denoms":[{"counts":[{"groupId":"OG000","value":"228"},{"groupId":"OG001","value":"113"}],"units":"Participants"}],"description":"EORTC QLQ-OV28 contains 28 items which assess a comprehensive range of relevant issues: abdominal/gastrointestinal (GI) symptoms, peripheral neuropathy, other chemotherapy side-effects, hormonal/menopausal symptoms, body image, attitude to disease/treatment and sexual functioning. The score for each domain and component score were scaled from 0 (minimum) to 100 (maximum). Higher scores indicate lower quality of life except for sexual functioning where higher scores indicate better quality of life.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received an oral dose of 45 milligram (mg) of MEK162 tablets (3 tablets of 15 mg) twice daily for each 28-day treatment cycle until disease progression, withdrawal of consent, initiation of subsequent anticancer therapy, lost to follow-up or death, whichever occurred first. Participants were followed up to 30 days after last dose of study intervention.","id":"OG000","title":"MEK 162"},{"description":"Participants received chemotherapies as per treating physician's choice in accordance to the institutional standard of care. Participants received one of the three intravenous (IV) infusion therapies: Liposomal doxorubicin 40 milligram per meter square (mg/m\\^2) on Day 1 of each 28-day cycle or Paclitaxel 80 mg/m\\^2 on Days 1, 8, and 15 of each 28-day cycle or, Topotecan 1.25 mg/m\\^2 on Days 1 through 5 of each 21-day cycle. Participants were followed up to 30 days after last dose of study intervention.","id":"OG001","title":"Physician's Choice"}],"paramType":"MEAN","populationDescription":"Analysis population included all randomized participants (228 participants in MEK162 group, 113 participants in physician's choice group).","reportingStatus":"POSTED","timeFrame":"Screening, every 8 weeks from randomization for the first 72 weeks (while on treatment), treatment discontinuation visit, 30-day safety follow-up visit","title":"Quality of Life Per European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Ovarian Cancer Module (QLQ-OV28)","type":"SECONDARY","unitOfMeasure":"Scores on a scale"}